Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
Global Economic Impact: Tuberculosis Costs the World $1.35 Trillion a Year
New research reveals tuberculosis costs the world $1.35 trillion annually, draining 0.8% of global economic potential and heavily impacting poorer nations.
FDA Grants Fast Track Designation to Apnimed's Sleep Apnea Therapy AD109
Apnimed receives FDA Fast Track designation for AD109, a first-in-class oral pharmacologic candidate designed to treat obstructive sleep apnea at night.
Clinical Trial Tests Stem Cell Infusion to Stabilize Alzheimer's Disease
A new clinical trial evaluates whether a single mesenchymal stem cell infusion combined with standard therapies can stabilize early Alzheimer's disease.
Preclinical Models Prove Crucial for Establishing Antibiotic PK/PD Targets
Experts emphasize the vital role of preclinical in vitro and animal models in establishing antibiotic PK/PD targets and the need to consider host factors.
Onco-Innovations Lands Big Pharma AI Deals & Advances PNKP Drug Trials
Onco-Innovations shares jump 79% as the micro-cap biotech secures AI collaborations with AstraZeneca and GSK and advances its PNKP inhibitor to trials.
Fact-Checking Hantavirus Plandemic Conspiracy Theories & Misinformation
Experts fact-check viral conspiracy theories claiming the recent Hantavirus outbreak is a planned pandemic, bioweapon, or COVID-19 vaccine side effect.
Boehringer Ingelheim Licenses Immunitas Preclinical Antibody for €407.5M
Boehringer Ingelheim licenses a preclinical antibody program from Immunitas Therapeutics to treat chronic inflammatory diseases in a deal worth up to €407.5M.
OPKO's ModeX Presents Preclinical In Vivo CAR-T Generation Data at ASGCT
ModeX Therapeutics will present preclinical data on MDX3001 at ASGCT 2026, showcasing in vivo CAR-T cell generation using an antibody-conjugated LNP platform.
Inhibrx Reports Positive Interim HexAgon Phase II Trial Results for HNSCC
Inhibrx Biosciences reveals positive interim Phase II data for INBRX-106 and pembrolizumab combination in treating advanced head and neck squamous cell cancer.
BMS and Hengrui Forge Historic $15.2B Licensing Deal for Oncology Drugs
Bristol Myers Squibb and Hengrui Pharma announce a $15.2B licensing deal for early-stage oncology, immunology, and haematology assets to combat patent cliffs.
Daraxonrasib Marks a New Era in Targeted Therapy for Pancreatic Cancers
Revolution Medicines’ daraxonrasib shows promising clinical results for metastatic pancreatic cancer, targeting previously undruggable KRAS mutations.
UK Paratroopers Execute Medical Airdrop on Tristan da Cunha for Hantavirus
British paratroopers and medics conducted a historic airdrop over Tristan da Cunha to deliver vital oxygen and care for a suspected hantavirus patient.
1
2
3
4
5
